Active Ingredient History
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction. Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 4)
Adjuvants, Anesthesia (Phase 2/Phase 3)
Airway Management (Phase 4)
Anesthesia (Phase 4)
Anesthesia and Analgesia (Phase 4)
Anesthesia, General (Phase 3)
Anesthesia Recovery Period (Phase 4)
Arthroplasty, Replacement, Hip (Phase 3)
Arthroplasty, Replacement, Knee (Phase 3)
Blood Coagulation (Phase 3)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 2)
Bronchoscopy (Phase 4)
Burns (Phase 3)
Cesarean Section (Phase 4)
Cholecystectomy, Laparoscopic (Phase 4)
Cholecystitis (Phase 4)
Colonic Pseudo-Obstruction (Phase 4)
Constipation (Phase 1)
Coronary Artery Disease (Phase 4)
Delayed Emergence from Anesthesia (Phase 4)
Diaphragm (Phase 3)
Elective Surgical Procedures (Phase 3)
Electromyography (Phase 4)
Emergence Delirium (Phase 4)
Endometriosis (Phase 4)
Extracorporeal Membrane Oxygenation (Phase 4)
Fecal Incontinence (Early Phase 1)
Fibrinolytic Agents (Phase 3)
Gallstones (Phase 4)
Gastrointestinal Motility (Phase 4)
General Surgery (Phase 4)
Headache (Phase 2/Phase 3)
Hypospadias (Phase 2/Phase 3)
Ileus (Phase 4)
Intestinal Diseases (Phase 4)
Intestinal Neoplasms (Phase 1)
Intra-Abdominal Hypertension (Phase 1)
Jaundice, Obstructive (Phase 1/Phase 2)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 4)
Knee Injuries (Phase 2/Phase 3)
Laparoscopy (Phase 4)
Laryngoscopy (Phase 4)
Leiomyoma (Phase 4)
Lung Diseases (Phase 4)
Mobility Limitation (Phase 4)
Muscle Fatigue (Phase 3)
Muscle Relaxants, Central (Phase 4)
Muscle Relaxation (Phase 4)
Muscle Weakness (Phase 4)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Neostigmine (Phase 4)
Neurogenic Bowel (Phase 1)
Neuromuscular Blockade (Phase 4)
Neuromuscular Blocking Agents (Phase 4)
Obesity (Phase 4)
Obesity, Morbid (Phase 2/Phase 3)
Pain, Postoperative (Phase 2/Phase 3)
Pancreatitis (Phase 1)
Paralysis (Phase 4)
Post-Dural Puncture Headache (Phase 4)
Postoperative Complications (Phase 4)
Postoperative Nausea and Vomiting (Phase 4)
Pregnancy (Phase 4)
Prostatic Neoplasms (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Respiratory-Gated Imaging Techniques (Phase 4)
Respiratory Insufficiency (Phase 4)
Respiratory Muscles (Phase 4)
Rocuronium (Phase 4)
Sepsis (Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Snoring (Early Phase 1)
Sphincter of Oddi Dysfunction (Phase 4)
Spinal Cord Injuries (Phase 4)
Spinal Curvatures (Phase 4)
Sugammadex (Phase 4)
Systemic Inflammatory Response Syndrome (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 4)
Uterine Prolapse (Phase 4)
Ventilators, Mechanical (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
